Press releases


Key Capital Licenses Immunitor Oral Pill Immunotherapeutics

New York, NY November 23, 2020 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that Key Biotec, a division of Key Capital, has entered into agreement with Immunitor group interests (“Immunitor”) to exclusively license its breakthrough patented oral tableted immunotherapeutics platform products for North, Central and South America (excluding Canada), the EU (excluding UK), Australia and New Zealand (the “Territory”).

Read More »